INTRODUCTION
============

The pathophysiology of type 2 diabetes mellitus (T2DM), a representative multifactorial disease, is very complex and encompasses decreased β-cell function, unsuppressed α-cell overactivity, increased hepatic glucose production, decreased glucose uptake in the skeletal muscle, increased lipolysis in the adipose tissue, decreased effect of incretin hormones, increased renal glucose reabsorption, and neurotransmitter abnormality \[[@B1]\]. Despite the highly complex nature of glucose homeostasis, there have been continuous efforts to build mathematical models for glucose metabolism using biological variables to predict glucose and insulin responses \[[@B2][@B3][@B4][@B5][@B6]\]. However, some efforts to adjust numerous variables resulted in an overfitting problem \[[@B7]\]. In this regard, Bergman\'s minimal model merits by requiring minimal numbers of parameters to estimate β-cell function and insulin sensitivity \[[@B8]\].

Two types of minimal models for the assessment of β-cell function and insulin sensitivity have been developed according to the different routes of glucose administration: intravenous glucose tolerance test (IVGTT) \[[@B8]\] and oral glucose tolerance test (OGTT), or mixed-meal tolerance test \[[@B3][@B9]\]. The IVGTT-based minimal model consists of glucose and insulin subsystems, where insulin in the plasma compartment passes the endothelium and enters a remote interstitial compartment to exert insulin action. In this model, if plasma insulin levels were solely measured, actual insulin secretion rates (ISRs) might be underestimated owing to the influence of different hepatic extractions of insulin \[[@B10]\]. Therefore, a C-peptide-based model was developed to overcome this shortcoming to estimate more accurate ISRs \[[@B11][@B12]\]. However, the intravenous administration of glucose is far from the physiologic way of glucose intake, which necessitates further improvement of the model by incorporating the physiology of oral glucose intake \[[@B13]\]. Since the OGTT is the gold standard method to determine glucose tolerance status, glucose, and insulin responses during the OGTT have been incorporated into mathematical models \[[@B2][@B4][@B14][@B15]\]. Among various oral glucose models, the oral minimal model can be easily applied to examine the dynamic physiology of glucose homeostasis, especially during the postprandial period. The oral minimal model comprises three submodels: The glucose minimal model assesses insulin secretion due to intestinal glucose absorption and consequent increases in the plasma glucose levels. The C-peptide minimal model determines how insulin controls the plasma glucose levels. The insulin and C-peptide minimal model was developed based on the C-peptide minimal model to assess the hepatic extraction of insulin. The oral minimal model can also be readily adapted to various situations by modifying its structure.

East Asians have a unique pathophysiology of T2DM. Compared to their Caucasian counterparts, early β-cell deterioration with relatively preserved insulin sensitivity is characteristic during the pathogenesis of T2DM in East Asians \[[@B16]\]. Therefore, it would be meaningful to test whether or not the oral minimal model can be used in the Korean population. In this study, we applied the oral minimal model to Korean subjects with T2DM and normal glucose tolerance (NGT) to assess β-cell function and insulin sensitivity.

METHODS
=======

Subjects and ethical statement
------------------------------

Our study included 14 patients with T2DM and 10 subjects with NGT, aged 18 to 75 years. The T2DM patients were diagnosed according to the criteria by the American Diabetes Association and had been treated with either lifestyle modifications or oral antidiabetic drugs. They did not have diabetic complications, such as retinopathy, microalbuminuria, or cardiovascular disease.

The study protocol was approved by the Institutional Review Board at the Seoul National University Hospital (registration number: H-1504-018-662) and was in compliance with the Declaration of Helsinki, as revised in 2000. Written informed consent was obtained from all of the participants before any study-related procedures.

Study procedures
----------------

Before visiting the Biomedical Research Center at the Seoul National University Hospital, all of the subjects had a 1-week washout period for oral antidiabetic drugs. They also fasted the night before the study day. All of the participants underwent a 180-minute, 75-g OGTT. Venous blood was drawn at 0, 15, 30, 60, 90, 120, and 180 minutes for the measurement of plasma glucose, insulin, and C-peptide levels. Glucose was measured by a glucose oxidase method (YSI 2300 STAT Plus analyzer; Yellow Springs Instruments, Yellow Springs, OH, USA). Insulin (DIAsource, Nivelles, Belgium) and C-peptide (Immunotech, Prague, Czech Republic) concentrations were measured with chemiluminescence immunoassay.

The mathematics of the oral minimal model
-----------------------------------------

The oral glucose minimal model and the oral C-peptide minimal model were adopted in this study. The oral glucose minimal model has two ordinary differential equations that represent the changes in plasma glucose and insulin concentrations. From previous studies \[[@B3][@B7][@B17]\], the following equations were derived: $$\frac{\text{dG}\left( t \right)}{\text{dt}} = - \left\lbrack {X\left\lbrack t \right\rbrack} \right\rbrack \times G\left( t \right) - S_{G} \times \left\lbrack {G\left\lbrack t \right\rbrack - G_{b}} \right\rbrack + \frac{R_{a}\left( t \right)}{V}\operatorname{,\quad}G\left( 0 \right) = G_{b}$$ $$\frac{dX\left( t \right)}{dt} = - p_{2} \times X\left( t \right) + p_{3} \times \left\lbrack {I\left( t \right)\operatorname{}I_{b}} \right\rbrack\operatorname{,\quad}X\left( 0 \right) = 0$$

G(t) is the plasma glucose concentration, V is the glucose distribution volume, and S~G~ is the fractional glucose effectiveness for promoting glucose disposal and altering the net hepatic glucose balance (Equation 1). R~a~(t) is the glucose appearance rate in plasma following oral glucose intake. X(t) represents the insulin action on glucose disposal and glucose production, and b denotes the basal value (Equations 1 and 2). Parameters, such as p~2~ and p~3~, are rate constants representing the dynamics and magnitude of insulin action. Namely, p~2~ is the rate constant in the remote insulin compartment (i.e., interstitial compartment) from which insulin action is derived, and p~3~ is used for the scaling of the amplitude of insulin action \[[@B17]\]. I(t) is the plasma insulin concentration (Equation 2). These equations describe the glucose response to a given insulin action and the intake of glucose from the gastrointestinal tract.

The oral C-peptide minimal model has four ordinary differential equations \[[@B3][@B14]\]. In this model, C-peptide kinetics is used instead of plasma insulin concentrations for the purpose of reflecting more accurate ISRs. $$\frac{dq_{1}\left( t \right)}{d} = - \left( {k_{01} + k_{21}} \right) \times q_{1}\left( t \right) + k_{12} \times q_{2}\left( t \right) + ISR\left( t \right)\operatorname{,\quad}c_{1}\left( t \right) = \frac{q_{1}\left( t \right)}{V}\operatorname{,\quad}q_{1}\left( 0 \right) = 0$$ $$\frac{dq_{2}\left( t \right)}{dt} = - k_{12} \times q_{2}\left( t \right) + k_{21} \times q_{1}\left( t \right)\operatorname{,\quad}q_{2}\left( 0 \right) = 0$$ $$ISR\left( t \right) = y\left( t \right) + K_{G} \times \frac{dG\left( t \right)}{dt}$$ $$\frac{\text{dy}\left( t \right)}{\text{dt}} = - \frac{1}{T}\left\lbrack {y\left\lbrack t \right\rbrack - \beta \times \left\lbrack {G\left\lbrack t \right\rbrack - G_{b}} \right\rbrack} \right\rbrack\operatorname{,\quad}y\left( 0 \right) = 0$$

Briefly, in Equation 3, q~1~ and q~2~ are the increased C-peptide amounts from the basal amounts in the accessible and remote compartments, respectively. ISR means increased C-peptide secretion rates from the basal rates. c~1~ is the increased C-peptide plasma concentration from the basal level. k~01~, k~12~, and k~21~ are rate constants characterizing C-peptides kinetics. c~1~ is the increased C-peptide concentration from the basal level, and y(t) is the insulin provision (i.e., the proportion of synthesized insulin reaching the β-cell membrane and ready to be secreted after a delay \[T\]). K~G~ and β are regarded as dynamic and static parameters, respectively.

The oral insulin and C-peptide minimal model is based on the oral C-peptide minimal model; a subsystem for the hepatic extraction of insulin is inserted. The insulin delivery rate (IDR) and hepatic insulin extraction (HE) can be determined in this model \[[@B12]\]. $$\frac{dI\left( t \right)}{dt} = - n \times I\left( t \right) + IDR\left( t \right)/V_{I}\operatorname{,\quad}I\left( 0 \right) = I_{b}$$

In this model, \'n\' is the rate constant of insulin elimination, V~I~ is the distribution volume of insulin, and (1--HE) means the fraction of ISR reaching the C-peptide accessible compartment.

Parameter estimation
--------------------

Three parameters (S~G~, p~2~, and p~3~) in Equations 1 and 2 were evaluated in the glucose minimal model using clinical data. Their values were obtained by minimizing the nonlinear least square function, which reflects the differences between the anticipated and measured points. Among the three parameters in the oral glucose minimal model, glucose effectiveness S~G~ and the ratio of p~2~ to p~3~ are important for characterizing the plasma glucose and insulin responses in each subject. Their values can be precisely estimated due to the inherent robustness of the model against errors in which the estimated ratio of p~2~ to p~3~ was nearly consistent, if p~2~ and p~3~ were respectively overestimated \[[@B18]\]. During this estimation process, all of the parameters were explored based on the reference values \[[@B19][@B20][@B21]\] within the parametric space using optimization techniques. One subject in the NGT group and two subjects in the T2DM group were excluded from this calculation via outlier reduction. The function of the absorption rate of glucose into the mesenteric circulation was derived from a previous study \[[@B21]\]. The simulated annealing method in the parametric space for optimization was performed \[[@B22]\]. Because the smooth slopes of curves were important in the calculations, we used simulated responses for estimation. The rate constants (k~01~, k~12~, and k~21~) characterizing the C-peptide kinetics were adapted from a previous study \[[@B23]\]. All of the processes were carried out for each subject using the MATLAB system (The Mathworks Inc., Natick, MA, USA).

Calculations
------------

Our goals of the calculations were two-fold. Our first goal was to compare the insulin sensitivity (S~I~) and β-cell function (i.e., basal, dynamic, static, and total responsivity indexes \[Φ~b~, Φ~d~, Φ~s~, and Φ~t~\]) between the NGT and T2DM groups. The second goal was to graphically present the dynamic, static, and total disposition indexes (DI~s~, DI~d~, and DI~t~) of the subjects using the DI metric to show the distribution of insulin sensitivity and β-cell responsivity of the NGT and T2DM groups.

In the oral minimal model, Φ~b~ reflects the insulin secretion at the basal state. Φ~d~ and Φ~s~, respectively, correspond to first and second phase of insulin secretion. Φ~t~ combines the effects of both Φ~d~ and Φ~s~ \[[@B14]\].

The indexes S~I~ and Φ~b~, Φ~d~, Φ~s~, and Φ~t~ of the subjects were calculated based on the derived parameters. In the glucose minimal model, S~I~ and S~G~ were calculated as follows \[[@B24]\]: $$S_{I} = \frac{p_{3}}{p_{2}}V\left( {10^{\operatorname{}5}\text{dL}/\text{kg}/\text{minperpmol}/L} \right)\operatorname{,\quad}S_{G} = p_{1}\left( \text{min}^{\operatorname{}1} \right)$$

In the C-peptide minimal model, the β-cell responsivity indexes represent the capacity of the β-cells to release insulin. They were approximated as follows \[[@B14][@B25]\]: $$\phi_{b} = \frac{k_{01}\text{CP}_{b}}{G_{b}}\left( {10^{\operatorname{}9}\text{min}^{\operatorname{}1}} \right)$$ $$\phi_{t} = \phi_{s} + \frac{\phi_{d}\left( G_{\text{max}} - G_{b} \right)}{\left. {\int_{0}^{\infty}\lbrack}G\left( t \right) - G_{b} \right\rbrack\text{dt}}\left( {10^{\operatorname{}9}\text{min}^{\operatorname{}1}} \right)$$

The DI~d~, DI~s~, and DI~t~ were calculated through multiplying Φ~d~, Φ~s~, and Φ~t~, respectively, by S~I~.

The basal hepatic insulin extraction ratio (HE~b~) and postglucose challenge hepatic insulin extraction ratio (HE~post~) were calculated. T~0~, 180 minutes in this study, is the time reaching the end of the tests \[[@B12]\]. $$\text{HE}_{b} = \frac{\text{ISR}_{b} - \text{IDR}_{b}}{\text{ISR}_{b}} = 1 - \frac{I_{b} \times n \times V_{I}}{\text{ISR}_{b}}\left( \% \right)$$ $$\text{HE}_{\text{post}} = \frac{{\int_{0}^{T_{0}}{\text{ISR}\left( t \right)\text{dt}}} - {\int_{0}^{T_{0}}{\text{IDR}\left( t \right)\text{dt}}}}{\int_{0}^{T_{0}}{\text{ISR}\left( t \right)\text{dt}}}\left( \% \right)$$

Statistical analysis
--------------------

To compare the variables between the NGT and T2DM groups, the Mann-Whitney test, chi-square test, Welch\'s test, and analysis of covariance for adjusting differences in age were performed. The oral minimal model indexes were log transformed for analysis and back transformed. The Spearman correlation analysis was also used. Prism 5.0 (GraphPad, San Diego, CA, USA), R 3.1.2 (The R Foundation, Vienna, Austria), and SPSS 19.0 (IBM Co., Armonk, NY, USA) software were used for statistical analysis. The significance level was set at 0.05 for the judgment of intergroup differences.

RESULTS
=======

The clinical characteristics of the participants are presented in [Table 1](#T1){ref-type="table"}. The T2DM group was older than the NGT group (mean±standard deviation, 53.8±9.4 years vs. 39.8±13.5 years, *P*\<0.019). The fasting glucose levels (146.2±27.6 mg/dL vs. 92.0±4.5 mg/dL, *P*\<0.001) and peak glucose levels during the OGTT (337.0±49.5 mg/dL vs. 175.9±17.1 mg/dL, *P*\<0.001) were higher in the T2DM group than the NGT group. The T2DM group had a longer delay in reaching the peak glucose levels than the NGT group (93.6±18.9 minutes vs. 49.0±13.5 minutes, *P*\<0.001). The body weight and body mass indexes were not significantly different between the NGT and T2DM groups.

Other indexes of insulin secretion or insulin action, such as postprandial C-peptide to glucose ratio (PCGR) \[[@B26]\], Matsuda index \[[@B27]\], and homeostasis model assessment of insulin resistance (HOMA-IR) \[[@B28]\], were compared between the NGT and T2DM groups and are shown in [Table 1](#T1){ref-type="table"}. The PCGR and Matsuda index were higher in the NGT group than the T2DM group (2.649±0.642 vs. 1.254±0.423, *P*\<0.001; 8.818±3.260 vs. 5.466±2.814, *P*=0.002, respectively). HOMA-IR was lower in the NGT group than the T2DM group (1.2±1.1 vs. 2.3±1.3, *P*=0.002).

Insulin sensitivity, β-cell responsivity indexes, and HE ratios
---------------------------------------------------------------

Insulin sensitivity and β-cell responsivity indexes were compared between the NGT and T2DM groups. As shown in [Fig. 1](#F1){ref-type="fig"}, the NGT group had a higher S~I~ than the T2DM group (20.0±8.2 \[×10^--5^ dL/kg/min per pmol/L\] vs. 13.3±11.8 \[×10^--5^ dL/kg/min per pmol/L\], *P*=0.024). The basal β-cell responsivity index (Φ~b~) was not significantly different between the NGT and T2DM groups (2.8±1.2 \[×10^--9^ min^--1^\] vs. 2.9±1.2 \[×10^--9^ min^--1^\], respectively, *P*=0.578, age-adjusted *P*=0.972). The Φ~d~, Φ~s~, and Φ~t~ were higher in the NGT group than the T2DM group (Φ~d~: 661.7±411.1 \[×10^--9^\] vs. 170.9±138.7 \[×10^--9^\], *P*\<0.001, age-adjusted *P*=0.005; Φ~s~: 33.5±9.4 \[×10^--9^ min^--1^\] vs. 13.9±6.5 \[×10^--9^ min^--1^\], *P*\<0.001, age-adjusted *P*\<0.001; Φ~t~: 41.9±13.2 \[×10^--9^ min^--1^\] vs. 15.5±7.2 \[×10^--9^ min^--1^\], *P*\<0.001, age-adjusted *P*\<0.001, respectively). The HE~b~ was not significantly different between the NGT and T2DM groups (55.20%±12.91% vs. 64.26%±9.27%, *P*=0.064). The HE~post~ appeared to be different between the NGT and T2DM groups (49.20%±20.79% vs. 66.99%±10.72%, *P*=0.028), which lost statistical significance after adjusting for age difference (*P*=0.141).

Disposition indexes between NGT and T2DM groups
-----------------------------------------------

The T2DM group had significantly lower DI~d~, DI~s~, and DI~t~ than the NGT group (DI~d~: 20.7±19.9 \[×10^--12^ dL/kg/min per pmol/L\] vs. 114.7±74.6 \[×10^--12^ dL/kg/min per pmol/L\], *P*=0.001, age-adjusted *P*\<0.001; DI~s~: 1.6±1.0 \[×10^--12^ dL/kg/min^2^ per pmol/L\] vs. 6.4±2.8 \[×10^--12^ dL/kg/min^2^ per pmol/L\], *P*\<0.001, age-adjusted *P*\<0.001; DI~t~: 1.8±1.1 \[×10^--12^ dL/kg/min^2^ per pmol/L\] vs. 7.9±3.4 \[×10^--12^ dL/kg/min^2^ per pmol/L\], *P*\<0.001, age-adjusted *P*\<0.001, respectively) ([Fig. 2](#F2){ref-type="fig"}). The hyperbolic relation is shown in the three DI metrics in [Fig. 3](#F3){ref-type="fig"}. The hyperbolic line for the T2DM group was located in the leftward and downward region of the NGT group.

Correlation between other indexes of insulin secretion or insulin action and oral minimal model indexes
-------------------------------------------------------------------------------------------------------

As shown in [Fig. 4](#F4){ref-type="fig"}, the PCGR has significant correlation with the dynamic and static responsivity indexes (*r*=0.77, *P*\<0.001 and *r*=0.89, *P*\<0.001, respectively). The Matsuda index was significantly correlated with insulin sensitivity (*r*=0.51, *P*=0.011), whereas HOMA-IR did not show any significance (*r*=--0.21, *P*=0.105).

DISCUSSION
==========

In this Korean study, S~I~ and β-cell responsivity indexes (Φ~d~, Φ~s~, and Φ~t~) were lower in the patients with T2DM than in the individuals with NGT. Compared to the NGT group, insulin sensitivity was 33.9% lower, and the Φ~d~, Φ~s~, and Φ~t~ were 74.1%, 58.3%, and 63.3% lower, respectively, in the T2DM group. Our results were in line with those of previous studies, showing decreased insulin sensitivity and insulin secretion in Korean T2DM patients, which were conducted with the euglycemic hyperinsulinemic clamp method \[[@B29]\], the hyperglycemic clamp method \[[@B30]\], or the IVGTT-based minimal model \[[@B31]\]. Compared to other methods, the oral minimal model has advantages for the separate assessment of insulin sensitivity and dynamic nature of β-cell responsivity simultaneously from a single data set. There are many surrogate measures for insulin sensitivity and/or β-cell function, such as HOMA methods \[[@B28]\], quantitative insulin sensitivity check index (QUICKI) \[[@B32]\], and Matsuda index \[[@B27]\]. Fasting measures, such as HOMA-insulin resistance and QUICKI, mainly reflect hepatic insulin sensitivity rather than peripheral insulin sensitivity \[[@B33][@B34]\]. Because HOMA β-cell function is also derived from fasting data \[[@B28]\], it cannot describe the dynamics of postprandial insulin secretion. In contrast, the S~I~ calculated by the oral minimal model represents not only hepatic but also peripheral insulin sensitivity \[[@B3][@B35][@B36]\]. Although the Matsuda index using the mean insulin and glucose responses during the OGTT correlates well with the insulin sensitivity measured by the euglycemic hyperinsulinemic clamp \[[@B27]\], this index is not matched for a measure of β-cell function that reflects the dynamic nature of postprandial insulin secretion. In this regard, the benefits of the oral minimal model are provision of comprehensive measures for insulin sensitivity, β-cell function, and hepatic extraction of insulin. In addition, the indexes obtained from the oral minimal model and other indexes of postchallenge insulin secretion and insulin sensitivity were well correlated.

The oral minimal model is simpler than the IVGTT-based minimal model \[[@B3][@B8]\], which requires much more frequent blood sampling and control for blood glucose concentrations. Therefore, it can be broadly applied for various clinical studies. First, the model can be used to assess characteristics of glucose metabolism in a large number of subjects. A previous study, which enrolled as many as 250 Japanese and Caucasian subjects, showed lower β-cell function and higher insulin sensitivity in the Japanese subjects than the Caucasian subjects \[[@B37]\]. Second, the oral minimal model can be used to assess the effect of antidiabetic drugs on insulin sensitivity and β-cell function, as shown elsewhere \[[@B38]\]. Taken together, the oral minimal model may reduce the burdens of effort in measuring physiologic parameters of glucose homeostasis in various forms of clinical research.

The oral minimal model has good expandability and can be readily modified in an engineering manner. To develop a further upgraded version of the oral minimal model, the incretin effect would be a candidate component to be incorporated in the model. If equations describing the incretin effect \[[@B39]\] were added to the oral minimal model, it could become a more physiologic model. Since a glucagon-adapted model has also been developed \[[@B40]\], it might be useful to assess the glycemic responses to specific antidiabetic drugs and to establish algorithms for the bihormonal artificial pancreas.

This study had some limitations. First, in this study, insulin and C-peptide were measured at 0, 15, and 30 minutes during the first 30 minutes, whereas other studies \[[@B14][@B25]\] included 0-, 10-, 20-, and 30-minute samples. Since the insulin response during the first 30 minutes is crucial to determine the dynamic β-cell responsivity index, more frequent measurements would support a more accurate estimation. Second, we did not directly validate the oral minimal model indexes with the values of the hyperglycemic clamp and the euglycemic hyperinsulinemic clamp studies, which are considered the gold standard methods for measuring insulin secretion and S~I~. Lastly, the subjects with prediabetes, such as impaired fasting glucose or impaired glucose tolerance, were not included in this study.

In this study, in accordance with the results of previously published studies using other physiologic methods in Koreans, the insulin sensitivity index, β-cell responsivity indexes, and disposition indexes obtained by the oral minimal model were generally lower in the T2DM group than the NGT group. Based on our results, the oral minimal model can also be applied to Koreans to evaluate insulin sensitivity and dynamics of insulin secretion using OGTT data.
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![The indexes for (A) insulin sensitivity (SI) and (B) basal, (C) dynamic, (D) static and (E) total β-cell responsivity (Φ~b~, Φ~d~, Φ~s~, and Φ~t~), (F) basal hepatic insulin extraction ratio (HE~b~), and (G) post-glucose challenge hepatic insulin extraction ratio (HE~post~). The Mann-Whitney test was used to compare the indexes between the groups. NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus; NS, not significant.](dmj-40-308-g001){#F1}

![The (A) dynamic, (B) static, and (C) total disposition indexes (DI~d~, DI~s~, and DI~t~) in the patients with type 2 diabetes mellitus (T2DM) and individuals with normal glucose tolerance (NGT). The Mann-Whitney test was used to compare the indexes between the groups.](dmj-40-308-g002){#F2}

![Distribution of insulin sensitivity and secretion in the patients with type 2 diabetes (T2DM) and individuals with normal glucose tolerance (NGT). The hyperbolae for the (A) dynamic, (B) static, (C) and total disposition (DI~s~, DI~d~, and DI~t~) indexes are shown for the NGT group (black line and open black circles) and the T2DM group (gray line and open gray circles) with a DI metric. Each circle or square represents a single subject. The subjects in each group presumably share the same disposition index, and a tendency toward the leftward and downward positioning in the T2DM patients can be observed. Φ~d~, dynamic; Φ~s~, static; Φ~t~, total β-cell responsivity.](dmj-40-308-g003){#F3}

![Correlation analyses between the indexes obtained in the oral minimal model and other indexes of insulin secretion or insulin sensitivity (S~I~). Spearman correlation analysis was used. Correlations of (A) dynamic (Φ~d~) and (B) static β-cell responsivity (Φ~s~) with postprandial C-peptide to glucose ratio (PCGR) are shown. Correlations of insulin sensitivity (S~I~) with (C) Matsuda index and (D) homeostasis model assessment of insulin resistance (HOMA-IR) are shown.](dmj-40-308-g004){#F4}

###### Clinical characteristics of the subjects

![](dmj-40-308-i001)

  Characteristic                      NGT (*n*=10)   T2DM (*n*=14)   *P* value
  ----------------------------------- -------------- --------------- -----------
  Sex, male/female                    8/2            9/5             0.653
  Age, yr                             39.8±13.5      53.8±9.4        0.019
  Body weight, kg                     66.6±15.0      67.6±14.4       0.898
  Body mass index, kg/m^2^            22.9±3.5       24.5±3.5        0.403
  Duration of diabetes mellitus, yr   NA             4.7±2.4         NA
  Fasting plasma glucose, mg/dL       92.0±4.5       146.2±27.6      \<0.001
  Peak plasma glucose, mg/dL          175.9±17.1     337.0±49.5      \<0.001
  Time for peak glucose, min          49.0±13.5      93.6±18.9       \<0.001
  PCGR                                2.6±0.6        1.3±0.4         \<0.001
  Matsuda index                       8.8±3.3        5.5±2.8         0.002
  HOMA-IR                             1.2±1.1        2.3±1.3         0.002

Values are presented as mean±standard deviation. *P* values were calculated using the chi-square test or the Mann-Whitney test, where appropriate.

NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus; NA, not applicable; PCGR, postprandial C-peptide to glucose ratio; HOMA-IR, homeostasis model assessment of insulin resistance.
